Status:
UNKNOWN
Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis
Lead Sponsor:
Fakultas Kedokteran Universitas Indonesia
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis
Eligibility Criteria
Inclusion
- age ≥18 years old
- ulcerative colitis patients who are treated by 5-aminosalicylic acid (5-ASA) 3x500 mg
- agreed to participate in this study
Exclusion
- ulcerative colitis patients who are treated by corticosteroid, immunosuppressive agents and biologic agents
- allergic to Ganoderma lucidum
- could not be randomised and participate in this study by clinical judgement
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT04029649
Start Date
August 1 2019
End Date
December 1 2020
Last Update
August 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital)
Jakarta, Jakarta Pusat, Indonesia, 10430